1 – 10 of 12
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2020
-
Mark
Efficacy of novel immunotherapy regimens in patients with metastatic melanoma with germline CDKN2A mutations
(
- Contribution to journal › Article
-
Mark
Desloratadine and loratadine use associated with improved melanoma survival
(
- Contribution to journal › Letter
-
Mark
Analysis of DNA methylation patterns in the tumor immune microenvironment of metastatic melanoma
(
- Contribution to journal › Article
- 2017
-
Mark
Germline Variation at CDKN2A and Associations with Nevus Phenotypes among Members of Melanoma Families
(
- Contribution to journal › Article
- 2014
-
Mark
Avoidance of sun exposure is a risk factor for all-cause mortality: results from the Melanoma in Southern Sweden cohort
(
- Contribution to journal › Article
-
Mark
Primary Melanoma Tumors from CDKN2A Mutation Carriers do not Belong to a Distinct Molecular Subclass.
(
- Contribution to journal › Article
-
Mark
Somatic BRAF and NRAS Mutations in Familial Melanomas with Known Germline CDKN2A Status: A GenoMEL Study
(
- Contribution to journal › Letter
- 2013
-
Mark
The clinical significance of BRAF and NRAS mutations in a clinic-based metastatic melanoma cohort.
(
- Contribution to journal › Article
- 2010
-
Mark
Swedish CDKN2A mutation carriers do not present the atypical mole syndrome phenotype.
(
- Contribution to journal › Article
- 2009
-
Mark
Selection criteria for genetic assessment of patients with familial melanoma
(
- Contribution to journal › Scientific review